Natera Ovarian Cancer Detection Assay
NCT03485651 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12
Last updated 2020-02-06
Summary
The purpose of this study is to enroll participants who present with an adnexal mass on imaging to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses. The study will collect blood, tissue, and health information from these individuals.
Conditions
- Adnexal Mass
Sponsors & Collaborators
-
Natera, Inc.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-12-14
- Primary Completion
- 2019-11-01
- Completion
- 2019-12-31
Countries
- United States
Study Locations
More Related Trials
-
Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 ·Status: COMPLETED
-
Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT01096394 ·Status: COMPLETED
-
Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
NCT00238342 ·Status: UNKNOWN ·Phase: NA
-
[68Ga]Ga-FAPI-46 PET/CT in Ovarian Cancer
NCT05903807 ·Status: RECRUITING ·Phase: PHASE2
-
New Biomarkers Evaluating Ovarian Cancer
NCT01466049 ·Status: COMPLETED
-
Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab
NCT03412630 ·Status: TERMINATED ·Phase: NA
-
Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer
NCT03691012 ·Status: UNKNOWN
-
Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test
NCT06445621 ·Status: RECRUITING
-
Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer
NCT04794322 ·Status: RECRUITING
-
A Study to Evaluate the Effectiveness and Tolerability of a Second Maintenance Treatment in Participants With Ovarian Cancer, Who Have Previously Received Polyadenosine 5'Diphosphoribose [Poly (ADP Ribose)] Polymerase Inhibitor (PARPi) Treatment.
NCT04239014 ·Status: WITHDRAWN ·Phase: PHASE2
-
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195 ·Status: RECRUITING ·Phase: NA
-
Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging
NCT05866679 ·Status: SUSPENDED ·Phase: PHASE1
-
Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcomes in Ovarian Cancer
NCT04830709 ·Status: RECRUITING
-
CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen
NCT00305838 ·Status: UNKNOWN ·Phase: PHASE2
-
Contrast-Enhanced Ultrasonography in Diagnosing Early-Stage Ovarian Cancer in Patients With an Adnexal Mass Undergoing Surgery to Remove the Ovary
NCT00626873 ·Status: COMPLETED ·Phase: PHASE1
-
CA-125 in Screening Patients at High Risk for Ovarian Cancer
NCT00080639 ·Status: WITHDRAWN
-
Signatera Assessment in Early-Stage Endometrial Cancer
NCT07339384 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Identifying Genetic Markers That Predict Response to Paclitaxel in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer
NCT00897806 ·Status: TERMINATED
-
Letrozole in Patients With Ovarian Tumors
NCT00505661 ·Status: TERMINATED ·Phase: PHASE2
-
Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer
NCT03297489 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer
NCT04971421 ·Status: UNKNOWN
-
Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer
NCT00288275 ·Status: TERMINATED
-
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265 ·Status: COMPLETED
-
Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer
NCT02973750 ·Status: COMPLETED
-
Venous Thromboembolic Complications in Ovarian Cancer
NCT02480790 ·Status: UNKNOWN